Federated Hermes Inc. Boosts Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Federated Hermes Inc. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 51.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 167,957 shares of the biotechnology company’s stock after acquiring an additional 56,930 shares during the quarter. Federated Hermes Inc. owned about 0.08% of BioCryst Pharmaceuticals worth $1,263,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the last quarter. Teacher Retirement System of Texas boosted its position in BioCryst Pharmaceuticals by 25.1% during the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock worth $438,000 after acquiring an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after acquiring an additional 91,998 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after acquiring an additional 127,708 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX opened at $7.04 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $9.50. The stock has a market capitalization of $1.47 billion, a P/E ratio of -11.54 and a beta of 1.75. The firm’s 50-day moving average is $7.93 and its two-hundred day moving average is $7.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BCRX shares. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.